Great Lakes NeuroTechnologies, a Cleveland-area company that promised more focus on DBS treatments as well as new products this year, has expanded its intellectual property in that area. The patent covers a wearable apparatus that positions an array of electrodes on the surface of the scalp and provides low-dose stimulation to the brain using transcranial direct current stimulation (tDCS) during different stages of sleep.
“While current approaches aim to target the location of stimulation to the brain, this approach is targeting the timing of stimulation by delivering it during sleep,” said Dustin Heldman, principal investigator and biomedical research manager.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Because the device method works while the patient is sleeping, it should limit patient discomfort while maybe targeting brain states likely to improve motor symptoms, according to the company.
The phase 1 clinical study for this method is ongoing.
Brian Kolkowski, EVP and general counsel at GLNT, said a growing patent portfolio that protects technology in the company’s targeted markets provides a strategic advantage.
Movement disorders, especially Parkinson’s, have been a large focus of GLNT, which also deals with telehealth and physiological monitoring for research and education.